Literature DB >> 10441168

The involvement of beta2-glycoprotein I (beta2-GPI) in human and murine atherosclerosis.

J George1, Y Shoenfeld, D Harats.   

Abstract

Atherosclerosis is a multifactorial process, the hallmark of which is fat deposition in the vessel wall. Autoimmune factors have recently been shown to play an important role in the initiation and progression of atherosclerosis; candidate autoantigens are oxidized lipids and heat shock proteins. beta2-glycoprotein I (beta2-GPI) is a highly glycosylated plasma protein that serves as a major antigenic target for autoimmune type antiphospholipid antibodies. Its major relevant property is binding to negatively charged phospholipids/surfaces. In the set of studies presented in this paper, we provide evidence pointing towards beta2-GPI as an influential determinant in murine and human atherogenesis. Thus, immunization of transgenic atherosclerosis-prone mice (apolipoprotein E and low-density lipoprotein receptor knockouts) with human beta2-GPI results in a brisk and sustained respective response that extends to cross-react with the 'self' murine beta2-GPI. Atherosclerosis is accelerated in both strains concomitant with the infiltration of CD4 lymphocytes in the aortic sinus of the mice. When human plaques were studied, it was found that beta2-GPI resides in the subendothelial regions and co-localizes with CD4 lymphocytes. Thus, the immune response towards beta2-GPI may play an important role in atherogenesis, serving as a possible target for antigen specific therapies. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441168     DOI: 10.1006/jaut.1999.0288

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  6 in total

Review 1.  Antiphospholipid antibodies and the endothelium.

Authors:  B J Hunt; M A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Systemic antiphospholipid syndrome and atherosclerosis.

Authors:  Luis J Jara; Gabriela Medina; Olga Vera-Lastra
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 4.  Pentraxins, anti-pentraxin antibodies, and atherosclerosis.

Authors:  N Bassi; S Zampieri; A Ghirardello; M Tonon; M Zen; F Cozzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

5.  Antibodies to age-β2 glycoprotein I in patients with anti-phospholipid antibody syndrome.

Authors:  M Sorice; B Buttari; A Capozzi; E Profumo; F Facchiano; S Truglia; S Recalchi; C Alessandri; F Conti; R Misasi; G Valesini; R Riganò
Journal:  Clin Exp Immunol       Date:  2016-02-15       Impact factor: 4.330

Review 6.  Antigen-induced immunomodulation in the pathogenesis of atherosclerosis.

Authors:  Natalia Milioti; Alexandra Bermudez-Fajardo; Manuel L Penichet; Ernesto Oviedo-Orta
Journal:  Clin Dev Immunol       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.